INTRODUCTION
============

Oropharyngeal and hypopharyngeal cancer are regarded as comparatively rare disease.^[@ref1])^ The National Comprehensive Cancer Network (NCCN) guidelines note some differences for each disease,^[@ref2])^ but treatment selection is broadly similar for these cancers: For T1--T2 N0 disease, definitive radiation therapy alone (or with additional chemotherapy in some cases) or an operation is selected. For T3--T4 or N+ disease, definitive radiotherapy with chemotherapy or an operation is selected. The reported prognostic predictors for oropharyngeal cancer include age, race, stage, history of cigarette smoking, status of lymph node metastases, and human papilloma virus (HPV) status.^[@ref3])^ The reported prognostic predictors for hypopharyngeal cancer include age, stage, and performance status (PS).^[@ref1],\ [@ref4],\ [@ref5])^

Some reports have mentioned that the maximum standardized uptake value (SUVmax) in ^18^F-fluorodeoxygulucose positron emission tomography (FDG-PET) may be a prognostic predictor in patients with head and neck cancer.^[@ref6]-[@ref9])^ Xie *et al*. examined previous reports in a meta-analysis, concluding that pSUVmax is a significant prognostic predictor for overall survival (OS), disease-free survival (DFS), and local control (LC) in patients with head and neck cancer.^[@ref10])^ However, most studies have not focused on individual types of head and neck cancer,^[@ref6]-[@ref10])^ and very few reports have focused on pharyngeal cancer.^[@ref11]-[@ref14])^ Moreover, although some reports noted that pSUVmax was a prognostic predictor for LC,^[@ref6],\ [@ref9],\ [@ref15])^ no report has analyzed the association between pSUVmax and LC as stratified by T-stage. As radiation oncologists, we would like to know whether the recurrence rate of primary tumors differs according to the pSUVmax, even between cases of the same T-stage. If the recurrence rate of tumors with higher pSUVmax is greater than that of tumors with lower pSUVmax, it may be necessary to increase the intensity of treatment, for example by administering a dose escalation or providing radiotherapy or surgery in combination with chemotherapy.

This study had 2 central aims. First, we sought to determine whether pSUVmax is a prognostic predictor in patients with oropharyngeal or hypopharyngeal cancer that was treated with definitive radiotherapy and followed-up for 5 years, as mentioned in previous reports.^[@ref6]-[@ref15])^ Second, we sought to determine whether the association between pSUVmax and LC differed according to T-stage.

MATERIALS AND METHODS
=====================

Patients
--------

This retrospective study was based on a review of the medical records of 136 patients who had oropharyngeal or hypopharyngeal cancer and received definitive radiotherapy at our institution between May 2006 and October 2011. All patients underwent a FDG-PET study before initial radiotherapy. The following patients were excluded from our analysis of the efficacy of FDG-PET examination: (1) 41 patients who were treated with a radical operation prior to radiotherapy, (2) 3 patients who had distant metastases, (3) 2 patients who had double cancers of the oropharynx and hypopharynx, and (4) 4 patients who were lost follow-up. Thus, a total of 86 patients were included in our analysis. Of these patients, 17 (20%) received radiotherapy alone and 69 (80%) received a combination of radiotherapy and chemotherapy.

As performed along with a routine physical examination, the pretreatment systematic evaluations included nasopharyngolaryngoscopy, tissue biopsy, gastrointestinal endoscopy, serum chemistry, chest radiography, contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) of the head and neck, and the FDG-PET scan. Clinical staging and treatment choices were determined at our institution's Head and Neck Cancer Board conference, using the information that had been derived from these examinations. This conference involved head and neck surgeons, radiation oncologists, medical oncologists, and radiologists.

Routine follow-up evaluations were performed every 1 month for the first year, every 3 months for next 2 years, and every 6 months thereafter. The follow-up included a routine physical examination and nasopharyngolaryngoscopy. Moreover, the assessment included repeated CT or MRI every 3--6 months, and PET or PET-CT every 6--12 months. Patient and tumor characteristics are summarized in [Table 1](#table1){ref-type="table"}. All patients provided prior written informed consent to undergo FDG-PET imaging and receive treatments. Our institution's review board approved this retrospective study (No. 1401). The study and all procedures were performed in accordance with the Helsinki Declaration of 1975, as revised in 1983.

###### 

Patient characteristics (n = 86)

  Characteristics                       n                              \%
  ------------------------------------- ------------------------------ -----------------
  Total no. of patients                 86                             
  Age, years                            median 65 (range 31--96)       
  Sex                                                                  
  Male/Female                           73/13                          85%/15%
  Performance status                                                   
  0--1/2--3                             72/14                          84%/16%
  Site of primary tumor                                                
  Oropharyngeal/Hypopharyngeal          51/35                          59%/41%
  TNM classification (UICC 2009)                                       
  T-stage                                                              
  T1/T2/T3/T4                           12/45/15/14                    14%/53%/17%/16%
  N-stage                                                              
  N0/N1/N2/N3                           21/14/47/4                     24%/16%/55%/5%
  Clinical stage                                                       
  StageI/StageII/StageIII/StageIVa--b   3/14/13/56                     3%/16%/15%/66%
  Value of pSUVmax                      median 8.0 (range 1.7--25.7)   
  Content of treatment                                                 
  RT only/CCRT                          17/69                          20%/80%
  Described dose (Gy)                   median 70 (range 60--74.4)     
  Histology                                                            
  Squamous cell carcinoma               83                             97%
  Lymphoepithelial carcinoma            2                              2%
  Carcinoma (NOS)                       1                              1%

Abbreviations: UICC, Union for International Cancer Control; pSUVmax, the maximum standardized uptake value of the primary site; RT, Radiotherapy; CCRT, Concurrent radiotherapy; NOS, not otherwise specified.

FDG-PET study
-------------

FDG-PET scans were performed with a PET scanner (Philips Allegro, Philips Medical System, Best, the Netherlands) that provided 45 trans-axial images at 4-mm intervals over a distance of 18.0 cm. The field of view and pixel size of the reconstructed images were 57.6 cm and 4.0 mm, respectively. The PET scans were acquired in a 3-dimensional mode with a matrix size of 128 × 128. Patients fasted for at least 6 hours before the PET study. None of the patients had a blood glucose level that exceeded 200 mg/dL before PET. Approximately 1 hour after IV administration of 222 to 333 MBq (6 to 9 mCi) of FDG, a static emission scan was performed with 2.5 to 3 min of acquisition in each bed position, covering the upper thigh to the ear with a total of 9--10 bed positions. Then, a transmission scan using a 137Cs ring was performed over the same area for 23 s per bed position. PET images were reconstructed using an ordered-subset expectation maximization iterative reconstruction algorithm (RAMLA).

After the FDG-PET scan had been completed, patients were moved to the CT room. The CT device was a multi-detector row CT system with an acceleration voltage of 120 kVp and a current of 80 mA. Both reconstructed PET and CT data were transferred to a workstation running viewing-dedicated software (Syntegra; SUN Microsystems, Milpitas, CA, USA) to create fused PET and CT images.

Image analysis
--------------

For the semiquantitative analysis of FDG uptake, regions of interest (ROIs) were manually drawn on the transaxial PET images around the focal FDG uptake zone in the primary tumor, as defined on the target lesions of the primary site on the transaxial PET images. The pSUVmax was then calculated using the following formula: SUV = activity concentration (kBq/ml) per injected dose (kBq) per body weight (kg). The measurements of pSUVmax were performed by experienced nuclear medicine physicians. For the survival analysis, the cut-off value of pSUVmax was determined based on receiver operating characteristic (ROC) curves.

Definitions of survival times
-----------------------------

OS was defined as the time between initial diagnosis and death from any cause. DFS was defined as the time between diagnosis and the first recurrence of the disease (loco-regional or distant recurrence), or death from any cause. LC was defined as the time between diagnosis and the first recurrence of the primary lesion.

Statistical analysis
--------------------

The data were analyzed using SPSS software, version 19 (SPSS Inc., Chicago, IL, USA). Pearson's χ^2^ test was used to assess measures of association in frequency tables. Spearman's correlation coefficient was used to analyze the correlations of pSUVmax with T-stage and clinical stage. OS, DFS, and LC were evaluated using Kaplan-Meier estimates and the log-rank test. In a multivariate analysis of DFS, the Cox proportional hazards model was used to assess the effects of patient characteristics and other potential predictive factors of significance. A *P*-value of 0.05 or less was considered statistically significant and all statistical tests were 2-sided.

RESULTS
=======

Of the 86 included patients, 51 had oropharyngeal cancer and 35 had hypopharyngeal cancer. Seventeen patients were diagnosed with stage I--II disease and 69 patients were diagnosed with stage III disease to stage IVa--b disease. Sixty-nine patients underwent concurrent chemotherapy (CCRT) and the remaining 17 patients were treated with radiotherapy alone because of advanced age, decreased respiratory function, or decreased renal function. In the CCRT group, the median described dose was 70 Gy (range, 60--70 Gy) in 2 Gy per fraction, with 5 fractions per week. The chemotherapy regimen was single-agent cisplatin for 2 or 3 cycles during radiotherapy. In the radiotherapy-alone group, the median described dose was 70 Gy in 35 fractions (range, 60--74.4 Gy). The field of therapy for each patient included the primary tumor site and regional lymph nodes. Therefore, whole-neck irradiation was used (40--50 Gy) and then a shrinking field was adopted as a boost irradiation. The patients' ages ranged from 31 to 96 years, with a median age of 65 years.

The median duration of follow-up for surviving patients was 60 months (range, 13--94 months). During the period of the follow-up evaluations, 29 patients developed recurrences: 12 had local recurrence only, 4 had local and regional lymph node recurrences, 2 had local and distant metastases, 1 had local and lymph node recurrences with distant metastases, 2 had regional lymph node recurrence only, 6 had distant metastases only, and 2 had regional lymph node recurrence with distant metastases. Twenty-three patients died of the disease and 5 patients died from other causes. Additionally, 5 patients were lost to follow-up. Although we did not determine whether these 5 patients had survived or died, 4 of them had no recurrence at the time of last follow-up, and the remaining patient had local recurrence and distant metastases at the time of last follow-up. The median survival time was 55 months in the entire cohort of included patients, while the 5-year OS and DFS were 65.9% and 60.0%, respectively.

The median pSUVmax was 8.0 (range, 1.7--25.7). Based on the ROC curve analysis, the appropriate pSUVmax cut-off values for DFS and LC were both determined to be 9.0. [Figure 1](#fig1){ref-type="fig"} shows the rates of DFS and LC as stratified by the pSUVmax cut-off value of 9.0. As can be seen from the DFS and LC curves, patients with higher pSUVmax developed significantly more recurrences than those with lower pSUVmax (DFS: 70.7% vs. 46.2% at 5-years, *p* = 0.009; LC: 89.8% vs. 59.6%, *p* = 0.001).

![Disease-free survival (DFS, panel A) and local control (LC, panel B) rates for the 86 patients, as stratified according to the standardized uptake value for the primary lesion (pSUVmax).](2186-3326-79-0027-g001){#fig1}

[Table 2](#table2){ref-type="table"} shows the correlations between various factors and pSUVmax, using the value of 9.0 as a cut-off. T-stage (*p* \< 0.0001), N-stage (*p* = 0.041), and clinical stage (*p* = 0.004) were significantly correlated with pSUVmax. Moreover, the correlations of pSUVmax with T-stage and clinical stage were analyzed using Spearman's correlation coefficient. There was a significant correlation between pSUVmax and T-stage (*r* = 0.557, *p* \< 0.001). On the other hand, there was a weaker correlation between pSUVmax and clinical stage (*r* = 0.341, *p* = 0.001).

###### 

Associations between pSUVmax (using 9.0 as a cut-off value) and clinical parameters

                     ≤ 9.0 (n = 49)   \> 9.0 (n = 37)   p-value\*
  ------------------ ---------------- ----------------- -------------
  Age, years                                            
  \< 70/≥ 70         35/14            23/14             p = 0.364
  Sex                                                   
  Male/Female        41/8             32/5              p = 0.718
  Tumor site                                            
  OPC/HPC            27/22            24/13             p = 0.362
  PS                                                    
  ≤ 1/≥ 2            43/6             29/8              p = 0.244
  Histology                                             
  Squamous/Other     46/3             37/0              p = 0.126
  Chemotherapy                                          
  +/--               37/12            32/5              p = 0.206
  T-stage                                               
  T1--2/T3--4        43/6             14/23             p \< 0.0001
  N-stage                                               
  N0/N1--3           16/33            5/32              p = 0.041
  Clinical stage                                        
  I--II/III--IVa-b   15/34            2/35              p = 0.004

Abbreviations: OPC, oropharyngeal cancer; HPC, hypopharyngeal cancer; PS, Performance status; pSUVmax, the maximum standardized uptake value of the primary site.

\* χ^2^ test

In the univariate analyses, T-stage (*p* = 0.001), N-stage (*p* = 0.039), clinical stage (*p* = 0.015), and pSUVmax (*p* = 0.009) were significant prognostic predictors for DFS (Table 3). Moreover, a multivariate analysis of DFS was performed, which included N-stage, clinical stage, and pSUVmax. Although the analysis did not reveal any statistically significant associations with DFS, we observed that pSUVmax showed borderline statistical significance as a prognostic factor for DFS ([Table 3](#table3){ref-type="table"}, hazard ratio = 0.499, 95% confidence interval = 0.245--1.014, *p* = 0.055).

###### 

Univariate and multivariate analyses of disease-free survival

  Factor             n       Number of recurrences/ deaths   p-value\*   p-value\*\*   HR (95% CI)
  ------------------ ------- ------------------------------- ----------- ------------- ------------------------
  Age, years                                                                           
  \< 70/≥ 70         58/28   23/11                           0.941                     
  Gender                                                                               
  Male/Female        73/13   32/2                            0.091                     
  Tumor site                                                                           
  OPC/HPC            51/35   18/16                           0.377                     
  PS                                                                                   
  ≤ 1/≥ 2            72/14   25/9                            0.079                     
  Histology                                                                            
  SCC/Other          83/3    34/0                            0.204                     
  Chemo                                                                                
  +/--               69/17   25/9                            0.129                     
  T-stage                                                                              
  T1--2/T3--4        57/29   16/18                           0.001                     
  N-stage                                                                              
  N0/N1--3           21/65   4/30                            0.039       0.731         0.774 (0.180--3.333)/1
  c stage                                                                              
  I--II/III--IVa-b   17/69   2/32                            0.017       0.297         0.340 (0.045--2.588)/1
  pSUVmax                                                                              
  ≤ 9.0/\> 9.0       49/37   14/20                           0.009       0.055         0.499 (0.245--1.014)/1

\* Univariate analyses using the log-rank test

\*\*Multivariate analyses using the Cox regression model

Abbreviations: n, number of patients; HR, hazard rate; CI, confidence interval; OPC, oropharyngeal cancer; HPC, hypopharyngeal cancer; PS, Performance status; SCC, squamous cell carcinoma; chemo, chemotherapy; c stage, clinical stage; pSUVmax, the maximum standardized uptake value of the primary site.

We additionally performed an analysis of LC that was stratified by T-stage ([Figure 2](#fig2){ref-type="fig"}). Among patients with T1--T2 disease, those with pSUVmax ≤9.0 and those with pSUVmax \>9.0 had significantly different rates of LC (*p* = 0.024). However, among patients with T3--T4 disease, there was no statistically significant difference between the pSUVmax groups (*p* = 0.735).

![Local control rates for the 57 patients with T1--T2 disease (A) and the 29 patients with T3--T4 disease (B), as stratified according to the standardized uptake value for the primary lesion (pSUVmax).](2186-3326-79-0027-g002){#fig2}

DISCUSSION
==========

There is a large difference between definitive radiotherapy and a radical operation in terms of whether a pathological diagnosis is obtained. If it is possible for us to know the condition of the disease in detail (e.g., whether the primary lesion has invaded the neighborhood, the details of histological type, and the presence of extra-nodal spread), such as is possible during an operation, then we can judge the need for later additional treatment. Thus, the existence of a minimally invasive predictor of radiotherapy's effectiveness could be useful for determining the intensity of treatment that should be provided to the patient, including whether an operation is necessary. In this regard, pSUVmax may be a useful predictive factor.

In this study, pSUVmax was an important prognostic predictor for DFS in patients who had oropharyngeal or hypopharyngeal cancer and were treated with definitive radiotherapy. Many reports have mentioned that pSUVmax may be a prognostic factor in patients with head and neck cancer.^[@ref6]-[@ref10])^ Nonetheless, the burdens of various primary tumors might differ, thus affecting FDG uptake, treatment response, and survival, all of which could cause biases. [Table 4](#table4){ref-type="table"} summarizes the previous reports that have focused on pharyngeal cancer.^[@ref11]-[@ref14])^ In these reports, it was shown that pSUVmax was related to survival rates, and the results of the present study are similar. A report by Kim *et al*. is especially interesting.^[@ref13])^ They analyzed 52 patients who had squamous cell carcinoma (SCC) of the oropharynx and were treated with surgical resection plus radiotherapy (n = 31) or radical radiotherapy plus chemotherapy (n = 21), concluding that patients with high pSUVmax may obtain a survival benefit from primary surgery followed by radiotherapy with or without chemotherapy, instead of from concomitant chemoradiotherapy. Thus, high ^18^F-FDG uptake may be useful for identifying pharyngeal cancers that require more aggressive treatment. Although we excluded patients with surgical resection from the present study to reduce the potential for confounding, an analysis that includes their data and carefully adjusts for confounding should be performed in the future.

###### 

Summary of reports in the literature on the efficacy of pre-treatment pSUVmax for patients with pharyngeal cancer

  Author                n    Subject   Treatment     Median follow-up (month)   Cut-off value of pSUVmax   p-value\*
  --------------------- ---- --------- ------------- -------------------------- -------------------------- ------------------
  Lee^(11)^ (2008)      41   NPC       RT/CCRT       40                         8                          p \< 0.007 (DFS)
  Lin^(12)^ (2012)      62   OPC+HPC   RT/CCRT       24                         11                         p \< 0.04 (PRFS)
  Kim^(13)^ (2007)      52   HPC       Ope/RT/CCRT   36                         6                          p = 0.036 (DFS)
  Suzuki^(14)^ (2014)   49   OPC+HPC   Ope/RT/CCRT   33                         8                          p \< 0.04 (OS)
  Present study         86   OPC+HPC   RT/CCRT       60                         9                          p = 0.009 (DFS)

Abbreviations: n, numbers of patients; pSUVmax, the maximum standardized uptake value of the primary site; NPC, nasopharyngeal cancer; OPC, oropharyngeal cancer; HPC, hypopharyngeal cancer; RT, radiotherapy alone; CCRT, concurrent radiotherapy; Ope, operation; DFS, disease-free survival; PRFS, primary tumor relapse-free survival; OS, overall survival.

\*Univariate analysis using the log-rank test

Interestingly, pSUVmax was predictive of LC rates in T1--T2 disease; even for the relatively small T1--T2 tumors, patients with higher pSUVmax had a worse LC rate than did patients with lower pSUVmax. Therefore, patients with tumors that have higher FDG uptake might need both more aggressive treatments and stricter follow-up. On the other hand, in our subgroup of patients with T3--T4 tumors, pSUVmax with a cut-off value of 9.0 was not observed to be significantly predictive of LC. The underlying reasons for the discrepancy between T1--T2 and T3--T4 disease remain unclear. One possible explanation is that the number of our patients who had T3--T4 tumors in the group with pSUVmax ≤ 9.0 (n = 6) did not provide enough power for the statistical analysis. Lin *et al*. analyzed the correlation between pSUVmax and the gross tumor volume (GTV) of the primary site in oropharyngeal and hypopharyngeal cancers, observing 2-year primary relapse-free survival rates of 92% and 47% for patients with a GTV ≤ 15 ml and pSUVmaxs of ≤ 11 and \> 11, respectively (*p* = 0.014).^[@ref12])^ This report provides indirect support for the results of the stratified analysis of T-stage in our study. Although no previous report has performed a similar stratified analysis of T-stage, some reports have mentioned significant associations between T-stage and the standardized uptake value of the primary site.^[@ref6],\ [@ref14],\ [@ref16])^Haerle*et al*. reported a significant association between pSUVmax and T-stage (*p* \< 0.001) in head and neck cancer.^[@ref16])^ Allal *et al*. reported that T1--T2 tumors had a lower median standardized uptake value than T3--T4 tumors (*p* = 0.004) in cases of head and neck cancer.^[@ref6])^ In an analysis of pharyngeal cancer, Suzuki *et al*. reported that patients with pSUVmax ≥ 8 had clinical T3--T4 stage disease more frequently than patients with pSUVmax \< 8 (*p* \< 0.03).^[@ref14])^ Our results are consistent with these previous reports, demonstrating significant associations between T-stage and pSUVmax (Table 2). In other words, higher T-stages are associated with higher pSUVmax.

Although SUVmax is convenient to measure and widely used, it has an important disadvantage: as a single-pixel measure that evaluates the most intense FDG uptake in the tumor, it may not be reflective of the total uptake for the whole tumor. Recently, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been investigated as novel indexes for analyses of standardized uptake value and tumor volume.^[@ref19]-[@ref23])^ (MTV is defined as the volume of tissues with increased FDG uptake, while TLG is calculated by taking the product of the tumor volume and the mean standardized uptake value.) Moon *et al*. reported that primary tumor TLG was an independent predictor for OS, whereas primary tumor MTV was not.^[@ref19])^ Garsa *et al*. found that primary tumor MTV was a significant predictor for OS and DFS, and that primary tumor TLG was a significant predictor for OS.^[@ref20])^ However, Higgins *et al*. reported that TLG was not prognostic.^[@ref21])^ Accordingly, there is currently no established agreement regarding the prognostic potential of MTV or TLG. In the present study of pSUVmax, we were not able to investigate MTV and TLG as prognostic predictors. Hence, this topic should be considered in the future.

The limitations to this study include its single-institution retrospective design and relatively small sample size (although a sufficient median duration of follow-up was employed). Thus, this study may have missed some confounding factors and include some biases.

In conclusion, in this study, pSUVmax was predictive of DFS and LC in patients with oropharyngeal or hypopharyngeal cancer that was treated with definitive radiotherapy. pSUVmax was strongly associated with LC in T1--T2 disease.
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